Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


Articles published in Breast Cancer Res

Retrieve available abstracts of 164 articles:
HTML format
Text format



Single Articles


    March 2019
  1. KENNEDY SP, Han JZR, Portman N, Nobis M, et al
    Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer.
    Breast Cancer Res. 2019;21:43.
    PubMed     Text format     Abstract available


  2. CLENDENEN TV, Ge W, Koenig KL, Afanasyeva Y, et al
    Breast cancer risk prediction in women aged 35-50 years: impact of including sex hormone concentrations in the Gail model.
    Breast Cancer Res. 2019;21:42.
    PubMed     Text format     Abstract available


  3. ECKER BL, Lee JY, Sterner CJ, Solomon AC, et al
    Impact of obesity on breast cancer recurrence and minimal residual disease.
    Breast Cancer Res. 2019;21:41.
    PubMed     Text format     Abstract available


  4. FORTNER RT, Sisti J, Chai B, Collins LC, et al
    Parity, breastfeeding, and breast cancer risk by hormone receptor status and molecular phenotype: results from the Nurses' Health Studies.
    Breast Cancer Res. 2019;21:40.
    PubMed     Text format     Abstract available


  5. VIJAY GV, Zhao N, Den Hollander P, Toneff MJ, et al
    GSK3beta regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
    Breast Cancer Res. 2019;21:37.
    PubMed     Text format     Abstract available


  6. ALZUBI MA, Turner TH, Olex AL, Sohal SS, et al
    Separation of breast cancer and organ microenvironment transcriptomes in metastases.
    Breast Cancer Res. 2019;21:36.
    PubMed     Text format     Abstract available


  7. GARCIA-ESTEVEZ L, Moreno-Bueno G
    Updating the role of obesity and cholesterol in breast cancer.
    Breast Cancer Res. 2019;21:35.
    PubMed     Text format     Abstract available


    February 2019
  8. MORTIMER J, Di Palma J, Schmid K, Ye Y, et al
    Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial.
    Breast Cancer Res. 2019;21:32.
    PubMed     Text format     Abstract available


  9. KOLB AD, Shupp AB, Mukhopadhyay D, Marini FC, et al
    Osteoblasts are "educated" by crosstalk with metastatic breast cancer cells in the bone tumor microenvironment.
    Breast Cancer Res. 2019;21:31.
    PubMed     Text format     Abstract available


  10. KENSLER KH, Regan MM, Heng YJ, Baker GM, et al
    Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98.
    Breast Cancer Res. 2019;21:30.
    PubMed     Text format     Abstract available


  11. CAO W, Li J, Hao Q, Vadgama JV, et al
    AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer.
    Breast Cancer Res. 2019;21:29.
    PubMed     Text format     Abstract available


  12. VAN BERCKELAER C, Rypens C, van Dam P, Pouillon L, et al
    Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression.
    Breast Cancer Res. 2019;21:28.
    PubMed     Text format     Abstract available


  13. GREER YE, Gilbert SF, Gril B, Narwal R, et al
    MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
    Breast Cancer Res. 2019;21:27.
    PubMed     Text format     Abstract available


  14. EMI M, Kim R, Tanabe K, Uchida Y, et al
    Correction to: Targeted therapy against Bcl-2-related proteins in breast cancer cells.
    Breast Cancer Res. 2019;21:26.
    PubMed     Text format     Abstract available


  15. NGUYEN B, Venet D, Lambertini M, Desmedt C, et al
    Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer.
    Breast Cancer Res. 2019;21:25.
    PubMed     Text format     Abstract available


  16. HSU YL, Yen MC, Chang WA, Tsai PH, et al
    CXCL17-derived CD11b(+)Gr-1(+) myeloid-derived suppressor cells contribute to lung metastasis of breast cancer through platelet-derived growth factor-BB.
    Breast Cancer Res. 2019;21:23.
    PubMed     Text format     Abstract available


  17. SMITH NG, Gyanchandani R, Shah OS, Gurda GT, et al
    Targeted mutation detection in breast cancer using MammaSeq.
    Breast Cancer Res. 2019;21:22.
    PubMed     Text format     Abstract available


  18. RODRIGUEZ-MARTINEZ A, de Miguel-Perez D, Ortega FG, Garcia-Puche JL, et al
    Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy.
    Breast Cancer Res. 2019;21:21.
    PubMed     Text format     Abstract available


  19. SCHWARZENBACHER D, Klec C, Pasculli B, Cerk S, et al
    MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors.
    Breast Cancer Res. 2019;21:20.
    PubMed     Text format     Abstract available


    January 2019
  20. WANG DY, Gendoo DMA, Ben-David Y, Woodgett JR, et al
    A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling.
    Breast Cancer Res. 2019;21:18.
    PubMed     Text format     Abstract available


  21. GAMPENRIEDER SP, Peer A, Weismann C, Meissnitzer M, et al
    Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
    Breast Cancer Res. 2019;21:19.
    PubMed     Text format     Abstract available


  22. BHAT K, Sandler K, Duhachek-Muggy S, Alli C, et al
    Serum erythropoietin levels, breast cancer and breast cancer-initiating cells.
    Breast Cancer Res. 2019;21:17.
    PubMed     Text format     Abstract available


  23. XIAO Y, Xia J, Li L, Ke Y, et al
    Associations between dietary patterns and the risk of breast cancer: a systematic review and meta-analysis of observational studies.
    Breast Cancer Res. 2019;21:16.
    PubMed     Text format     Abstract available


  24. FLEMING RM, Fleming MR, Chaudhuri TK, Dooley WC, et al
    Letter to the Editor: A response to Hruska's case study on molecular breast imaging and the need for true tissue quantification.
    Breast Cancer Res. 2019;21:15.
    PubMed     Text format    


  25. GHAFFARI A, Hoskin V, Turashvili G, Varma S, et al
    Intravital imaging reveals systemic ezrin inhibition impedes cancer cell migration and lymph node metastasis in breast cancer.
    Breast Cancer Res. 2019;21:12.
    PubMed     Text format     Abstract available


  26. NOKIN MJ, Bellier J, Durieux F, Peulen O, et al
    Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancer.
    Breast Cancer Res. 2019;21:11.
    PubMed     Text format     Abstract available


  27. STRAND F, Azavedo E, Hellgren R, Humphreys K, et al
    Localized mammographic density is associated with interval cancer and large breast cancer: a nested case-control study.
    Breast Cancer Res. 2019;21:8.
    PubMed     Text format     Abstract available


  28. CAMILIO KA, Wang MY, Mauseth B, Waagene S, et al
    Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model.
    Breast Cancer Res. 2019;21:9.
    PubMed     Text format     Abstract available


  29. JARMAN EJ, Ward C, Turnbull AK, Martinez-Perez C, et al
    HER2 regulates HIF-2alpha and drives an increased hypoxic response in breast cancer.
    Breast Cancer Res. 2019;21:10.
    PubMed     Text format     Abstract available


  30. LEHUEDE C, Li X, Dauvillier S, Vaysse C, et al
    Adipocytes promote breast cancer resistance to chemotherapy, a process amplified by obesity: role of the major vault protein (MVP).
    Breast Cancer Res. 2019;21:7.
    PubMed     Text format     Abstract available


  31. KIJEWSKA M, Viski C, Turrell F, Fitzpatrick A, et al
    Using an in-vivo syngeneic spontaneous metastasis model identifies ID2 as a promoter of breast cancer colonisation in the brain.
    Breast Cancer Res. 2019;21:4.
    PubMed     Text format     Abstract available


  32. HOFFMAN J, Fejerman L, Hu D, Huntsman S, et al
    Identification of novel common breast cancer risk variants at the 6q25 locus among Latinas.
    Breast Cancer Res. 2019;21:3.
    PubMed     Text format     Abstract available


  33. GAO C, Xiao G, Piersigilli A, Gou J, et al
    Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.
    Breast Cancer Res. 2019;21:5.
    PubMed     Text format     Abstract available


  34. SELLI C, Turnbull AK, Pearce DA, Li A, et al
    Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours.
    Breast Cancer Res. 2019;21:2.
    PubMed     Text format     Abstract available


    December 2018
  35. HUDSON S, Vik Hjerkind K, Vinnicombe S, Allen S, et al
    Adjusting for BMI in analyses of volumetric mammographic density and breast cancer risk.
    Breast Cancer Res. 2018;20:156.
    PubMed     Text format     Abstract available


  36. NICKSON C, Procopio P, Velentzis LS, Carr S, et al
    Prospective validation of the NCI Breast Cancer Risk Assessment Tool (Gail Model) on 40,000 Australian women.
    Breast Cancer Res. 2018;20:155.
    PubMed     Text format     Abstract available


  37. WU WY, Tornberg S, Elfstrom KM, Liu X, et al
    Overdiagnosis in the population-based organized breast cancer screening program estimated by a non-homogeneous multi-state model: a cohort study using individual data with long-term follow-up.
    Breast Cancer Res. 2018;20:153.
    PubMed     Text format     Abstract available


  38. BHARDWAJ A, Singh H, Trinidad CM, Albarracin CT, et al
    The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer.
    Breast Cancer Res. 2018;20:150.
    PubMed     Text format     Abstract available


  39. BROOKS JD, Comen EA, Reiner AS, Orlow I, et al
    CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study.
    Breast Cancer Res. 2018;20:149.
    PubMed     Text format     Abstract available


  40. KUS K, Kij A, Zakrzewska A, Jasztal A, et al
    Alterations in arginine and energy metabolism, structural and signalling lipids in metastatic breast cancer in mice detected in plasma by targeted metabolomics and lipidomics.
    Breast Cancer Res. 2018;20:148.
    PubMed     Text format     Abstract available


    November 2018
  41. MERINO VF, Cho S, Nguyen N, Sadik H, et al
    Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.
    Breast Cancer Res. 2018;20:145.
    PubMed     Text format     Abstract available


  42. WEGE AK, Chittka D, Buchholz S, Klinkhammer-Schalke M, et al
    HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women.
    Breast Cancer Res. 2018;20:139.
    PubMed     Text format     Abstract available


  43. VETTER M, Landin J, Szczerba BM, Castro-Giner F, et al
    Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer.
    Breast Cancer Res. 2018;20:141.
    PubMed     Text format     Abstract available


  44. FRISK G, Ekberg S, Lidbrink E, Eloranta S, et al
    No association between low-dose aspirin use and breast cancer outcomes overall: a Swedish population-based study.
    Breast Cancer Res. 2018;20:142.
    PubMed     Text format     Abstract available


  45. CHATTERJEE G, Pai T, Hardiman T, Avery-Kiejda K, et al
    Molecular patterns of cancer colonisation in lymph nodes of breast cancer patients.
    Breast Cancer Res. 2018;20:143.
    PubMed     Text format     Abstract available


  46. LEECH AO, Vellanki SH, Rutherford EJ, Keogh A, et al
    Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings.
    Breast Cancer Res. 2018;20:140.
    PubMed     Text format     Abstract available


  47. BECKWITT CH, Brufsky A, Oltvai ZN, Wells A, et al
    Statin drugs to reduce breast cancer recurrence and mortality.
    Breast Cancer Res. 2018;20:144.
    PubMed     Text format     Abstract available


  48. RHOST S, Hughes E, Harrison H, Rafnsdottir S, et al
    Sortilin inhibition limits secretion-induced progranulin-dependent breast cancer progression and cancer stem cell expansion.
    Breast Cancer Res. 2018;20:137.
    PubMed     Text format     Abstract available


  49. VAN DER WILLIK KD, Koppelmans V, Hauptmann M, Compter A, et al
    Inflammation markers and cognitive performance in breast cancer survivors 20 years after completion of chemotherapy: a cohort study.
    Breast Cancer Res. 2018;20:135.
    PubMed     Text format     Abstract available


  50. RAMIN C, May BJ, Roden RBS, Orellana MM, et al
    Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study.
    Breast Cancer Res. 2018;20:134.
    PubMed     Text format     Abstract available


  51. SUCHANSKI J, Grzegrzolka J, Owczarek T, Pasikowski P, et al
    Sulfatide decreases the resistance to stress-induced apoptosis and increases P-selectin-mediated adhesion: a two-edged sword in breast cancer progression.
    Breast Cancer Res. 2018;20:133.
    PubMed     Text format     Abstract available


  52. HOPPER JL, Dite GS, MacInnis RJ, Liao Y, et al
    Age-specific breast cancer risk by body mass index and familial risk: prospective family study cohort (ProF-SC).
    Breast Cancer Res. 2018;20:132.
    PubMed     Text format     Abstract available


    October 2018
  53. MCKNIGHT BN, Viola-Villegas NT
    Monitoring Src status after dasatinib treatment in HER2+ breast cancer with (89)Zr-trastuzumab PET imaging.
    Breast Cancer Res. 2018;20:130.
    PubMed     Text format     Abstract available


  54. LIU X, Cao M, Palomares M, Wu X, et al
    Metastatic breast cancer cells overexpress and secrete miR-218 to regulate type I collagen deposition by osteoblasts.
    Breast Cancer Res. 2018;20:127.
    PubMed     Text format     Abstract available


  55. HORTOBAGYI GN
    Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial.
    Breast Cancer Res. 2018;20:123.
    PubMed     Text format     Abstract available


  56. DIELI-CONWRIGHT CM, Courneya KS, Demark-Wahnefried W, Sami N, et al
    Aerobic and resistance exercise improves physical fitness, bone health, and quality of life in overweight and obese breast cancer survivors: a randomized controlled trial.
    Breast Cancer Res. 2018;20:124.
    PubMed     Text format     Abstract available


  57. BORGEN E, Rypdal MC, Sosa MS, Renolen A, et al
    NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients.
    Breast Cancer Res. 2018;20:120.
    PubMed     Text format     Abstract available


  58. ANDERSEN ZJ, Jorgensen JT, Elsborg L, Lophaven SN, et al
    Long-term exposure to road traffic noise and incidence of breast cancer: a cohort study.
    Breast Cancer Res. 2018;20:119.
    PubMed     Text format     Abstract available


  59. SWERDLOW AJ, Wright LB, Schoemaker MJ, Jones ME, et al
    Maternal breast cancer risk in relation to birthweight and gestation of her offspring.
    Breast Cancer Res. 2018;20:110.
    PubMed     Text format     Abstract available


  60. UNGERLEIDER NA, Rao SG, Shahbandi A, Yee D, et al
    Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment.
    Breast Cancer Res. 2018;20:115.
    PubMed     Text format     Abstract available


  61. SETHURAMAN A, Brown M, Krutilina R, Wu ZH, et al
    BHLHE40 confers a pro-survival and pro-metastatic phenotype to breast cancer cells by modulating HBEGF secretion.
    Breast Cancer Res. 2018;20:117.
    PubMed     Text format     Abstract available


    September 2018
  62. YANG L, Tian Y, Leong WS, Song H, et al
    Efficient and tumor-specific knockdown of MTDH gene attenuates paclitaxel resistance of breast cancer cells both in vivo and in vitro.
    Breast Cancer Res. 2018;20:113.
    PubMed     Text format     Abstract available


  63. ABUBAKAR M, Sung H, Bcr D, Guida J, et al
    Breast cancer risk factors, survival and recurrence, and tumor molecular subtype: analysis of 3012 women from an indigenous Asian population.
    Breast Cancer Res. 2018;20:114.
    PubMed     Text format     Abstract available


  64. GAO P, Wang X, Jin Y, Hu W, et al
    Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells.
    Breast Cancer Res. 2018;20:112.
    PubMed     Text format     Abstract available


  65. SCHOFFSKI P, Cresta S, Mayer IA, Wildiers H, et al
    A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer.
    Breast Cancer Res. 2018;20:109.
    PubMed     Text format     Abstract available


  66. ROSATO RR, Davila-Gonzalez D, Choi DS, Qian W, et al
    Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
    Breast Cancer Res. 2018;20:108.
    PubMed     Text format     Abstract available


  67. BOUSQUENAUD M, Fico F, Solinas G, Ruegg C, et al
    Obesity promotes the expansion of metastasis-initiating cells in breast cancer.
    Breast Cancer Res. 2018;20:104.
    PubMed     Text format     Abstract available


  68. LEONTOVICH AA, Jalalirad M, Salisbury JL, Mills L, et al
    NOTCH3 expression is linked to breast cancer seeding and distant metastasis.
    Breast Cancer Res. 2018;20:105.
    PubMed     Text format     Abstract available


  69. DU T, Sikora MJ, Levine KM, Tasdemir N, et al
    Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer.
    Breast Cancer Res. 2018;20:106.
    PubMed     Text format     Abstract available


  70. BUUS R, Yeo B, Brentnall AR, Klintman M, et al
    Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer.
    Breast Cancer Res. 2018;20:103.
    PubMed     Text format     Abstract available


  71. WU J, Li X, Teng X, Rubin DL, et al
    Magnetic resonance imaging and molecular features associated with tumor-infiltrating lymphocytes in breast cancer.
    Breast Cancer Res. 2018;20:101.
    PubMed     Text format     Abstract available


    August 2018
  72. HUTCHESON IR, Knowlden JM, Hiscox SE, Barrow D, et al
    Correction to: Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
    Breast Cancer Res. 2018;20:98.
    PubMed     Text format     Abstract available


  73. DA CRUZ RS, Carney EJ, Clarke J, Cao H, et al
    Paternal malnutrition programs breast cancer risk and tumor metabolism in offspring.
    Breast Cancer Res. 2018;20:99.
    PubMed     Text format     Abstract available


  74. SHAIK AN, Ruterbusch JJ, Abdulfatah E, Shrestha R, et al
    Breast fibroadenomas are not associated with increased breast cancer risk in an African American contemporary cohort of women with benign breast disease.
    Breast Cancer Res. 2018;20:91.
    PubMed     Text format     Abstract available


  75. ORTEGA-OLVERA C, Ulloa-Aguirre A, Angeles-Llerenas A, Mainero-Ratchelous FE, et al
    Thyroid hormones and breast cancer association according to menopausal status and body mass index.
    Breast Cancer Res. 2018;20:94.
    PubMed     Text format     Abstract available


  76. BIERMANN J, Parris TZ, Nemes S, Danielsson A, et al
    Clonal relatedness in tumour pairs of breast cancer patients.
    Breast Cancer Res. 2018;20:96.
    PubMed     Text format     Abstract available


  77. KATCHMAN BA, Tolgay Ocal I, Cunliffe HE, Chang YH, et al
    Correction to: Expression of quiescin sulfhydryl oxidase 1 is associated with a highly invasive phenotype and correlates with a poor prognosis in luminal B breast cancer.
    Breast Cancer Res. 2018;20:89.
    PubMed     Text format     Abstract available


  78. PENKERT J, Schmidt G, Hofmann W, Schubert S, et al
    Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
    Breast Cancer Res. 2018;20:87.
    PubMed     Text format     Abstract available


  79. LIANG X, Vacher S, Boulai A, Bernard V, et al
    Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
    Breast Cancer Res. 2018;20:88.
    PubMed     Text format     Abstract available


  80. SMEDA M, Kieronska A, Adamski MG, Proniewski B, et al
    Nitric oxide deficiency and endothelial-mesenchymal transition of pulmonary endothelium in the progression of 4T1 metastatic breast cancer in mice.
    Breast Cancer Res. 2018;20:86.
    PubMed     Text format     Abstract available


  81. POGUE BW
    Can novel technologies improve breast conserving surgery?
    Breast Cancer Res. 2018;20:85.
    PubMed     Text format    


  82. DE ROON M, May AM, McTiernan A, Scholten RJPM, et al
    Effect of exercise and/or reduced calorie dietary interventions on breast cancer-related endogenous sex hormones in healthy postmenopausal women.
    Breast Cancer Res. 2018;20:81.
    PubMed     Text format     Abstract available


  83. DIAMOND JR, Eckhardt SG, Pitts TM, van Bokhoven A, et al
    A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer.
    Breast Cancer Res. 2018;20:82.
    PubMed     Text format     Abstract available


    July 2018
  84. ASANO A, Ueda S, Kuji I, Yamane T, et al
    Intracellular hypoxia measured by (18)F-fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen receptor-positive breast cancer.
    Breast Cancer Res. 2018;20:78.
    PubMed     Text format     Abstract available


  85. JENSEN MB, Laenkholm AV, Nielsen TO, Eriksen JO, et al
    The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer.
    Breast Cancer Res. 2018;20:79.
    PubMed     Text format     Abstract available


  86. LI JT, Wang LF, Zhao YL, Yang T, et al
    Retraction Note: Nuclear factor of activated T cells 5 maintained by Hotair suppression of miR-568 upregulates S100 calcium binding protein A4 to promote breast cancer metastasis.
    Breast Cancer Res. 2018;20:77.
    PubMed     Text format     Abstract available


  87. SHINDE A, Wilmanski T, Chen H, Teegarden D, et al
    Pyruvate carboxylase supports the pulmonary tropism of metastatic breast cancer.
    Breast Cancer Res. 2018;20:76.
    PubMed     Text format     Abstract available


  88. PAPADAKI C, Stratigos M, Markakis G, Spiliotaki M, et al
    Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer.
    Breast Cancer Res. 2018;20:72.
    PubMed     Text format     Abstract available


  89. O'BRIEN KM, Sandler DP, Xu Z, Kinyamu HK, et al
    Vitamin D, DNA methylation, and breast cancer.
    Breast Cancer Res. 2018;20:70.
    PubMed     Text format     Abstract available


  90. SHAPIRA M, Kakiashvili E, Rosenberg T, Hershko DD, et al
    Correction to: The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells.
    Breast Cancer Res. 2018;20:68.
    PubMed     Text format     Abstract available


  91. SJOSTROM M, Staaf J, Eden P, Warnberg F, et al
    Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors.
    Breast Cancer Res. 2018;20:64.
    PubMed     Text format     Abstract available


  92. CHANG XZ, Li DQ, Hou YF, Wu J, et al
    Correction to: Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.
    Breast Cancer Res. 2018;20:63.
    PubMed     Text format     Abstract available


    June 2018
  93. DIECI MV, Tsvetkova V, Orvieto E, Piacentini F, et al
    Immune characterization of breast cancer metastases: prognostic implications.
    Breast Cancer Res. 2018;20:62.
    PubMed     Text format     Abstract available


  94. LIM KT, Cosgrave N, Hill AD, Young LS, et al
    Correction to: Nongenomic oestrogen signalling in oestrogen receptor negative breast cancer cells: a role for the angiotensin II receptor AT1.
    Breast Cancer Res. 2018;20:61.
    PubMed     Text format     Abstract available


  95. SUROV A, Clauser P, Chang YW, Li L, et al
    Can diffusion-weighted imaging predict tumor grade and expression of Ki-67 in breast cancer? A multicenter analysis.
    Breast Cancer Res. 2018;20:58.
    PubMed     Text format     Abstract available


  96. DONZELLI S, Milano E, Pruszko M, Sacconi A, et al
    Expression of ID4 protein in breast cancer cells induces reprogramming of tumour-associated macrophages.
    Breast Cancer Res. 2018;20:59.
    PubMed     Text format     Abstract available


  97. ALVES CL, Elias D, Lyng MB, Bak M, et al
    SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
    Breast Cancer Res. 2018;20:60.
    PubMed     Text format     Abstract available


  98. ZHU Q, Tannenbaum S, Kurtzman SH, DeFusco P, et al
    Identifying an early treatment window for predicting breast cancer response to neoadjuvant chemotherapy using immunohistopathology and hemoglobin parameters.
    Breast Cancer Res. 2018;20:56.
    PubMed     Text format     Abstract available


  99. SEVINSKY CJ, Khan F, Kokabee L, Darehshouri A, et al
    NDRG1 regulates neutral lipid metabolism in breast cancer cells.
    Breast Cancer Res. 2018;20:55.
    PubMed     Text format     Abstract available


  100. JIN K, Pandey NB, Popel AS
    Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis.
    Breast Cancer Res. 2018;20:54.
    PubMed     Text format     Abstract available


  101. GILES ED, Jindal S, Wellberg EA, Schedin T, et al
    Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer.
    Breast Cancer Res. 2018;20:50.
    PubMed     Text format     Abstract available


  102. NORTON N, Fox N, McCarl CA, Tenner KS, et al
    Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer.
    Breast Cancer Res. 2018;20:52.
    PubMed     Text format     Abstract available


  103. KRIKKEN E, Khlebnikov V, Zaiss M, Jibodh RA, et al
    Amide chemical exchange saturation transfer at 7 T: a possible biomarker for detecting early response to neoadjuvant chemotherapy in breast cancer patients.
    Breast Cancer Res. 2018;20:51.
    PubMed     Text format     Abstract available


  104. TAWARA K, Bolin C, Koncinsky J, Kadaba S, et al
    OSM potentiates preintravasation events, increases CTC counts, and promotes breast cancer metastasis to the lung.
    Breast Cancer Res. 2018;20:53.
    PubMed     Text format     Abstract available


  105. LEWIS-WAMBI JS, Kim HR, Wambi C, Patel R, et al
    Correction to: Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis.
    Breast Cancer Res. 2018;20:57.
    PubMed     Text format     Abstract available


  106. WANG C, Brentnall AR, Cuzick J, Harkness EF, et al
    Exploring the prediction performance for breast cancer risk based on volumetric mammographic density at different thresholds.
    Breast Cancer Res. 2018;20:49.
    PubMed     Text format     Abstract available


  107. LARSSON AM, Jansson S, Bendahl PO, Levin Tykjaer Jorgensen C, et al
    Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
    Breast Cancer Res. 2018;20:48.
    PubMed     Text format     Abstract available


  108. RIBAS R, Pancholi S, Rani A, Schuster E, et al
    Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
    Breast Cancer Res. 2018;20:44.
    PubMed     Text format     Abstract available


  109. PAPANASTASIOU AD, Sirinian C, Kalofonos HP
    Correction to: Identification of novel human RANK isoforms generated through alternative splicing. Implications in breast cancer cell survival and migration.
    Breast Cancer Res. 2018;20:47.
    PubMed     Text format     Abstract available


  110. BENSEN JT, Graff M, Young KL, Sethupathy P, et al
    A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women.
    Breast Cancer Res. 2018;20:45.
    PubMed     Text format     Abstract available


  111. HRUSKA CB, Geske JR, Swanson TN, Mammel AN, et al
    Quantitative background parenchymal uptake on molecular breast imaging and breast cancer risk: a case-control study.
    Breast Cancer Res. 2018;20:46.
    PubMed     Text format     Abstract available


    May 2018
  112. JOHNSTON AN, Bu W, Hein S, Garcia S, et al
    Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions.
    Breast Cancer Res. 2018;20:42.
    PubMed     Text format     Abstract available


  113. ALLOUCHERY V, Beaussire L, Perdrix A, Sefrioui D, et al
    Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients.
    Breast Cancer Res. 2018;20:40.
    PubMed     Text format     Abstract available


  114. KISH JK, Ward MA, Garofalo D, Ahmed HV, et al
    Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval.
    Breast Cancer Res. 2018;20:37.
    PubMed     Text format     Abstract available


  115. CHEN BT, Sethi SK, Jin T, Patel SK, et al
    Assessing brain volume changes in older women with breast cancer receiving adjuvant chemotherapy: a brain magnetic resonance imaging pilot study.
    Breast Cancer Res. 2018;20:38.
    PubMed     Text format     Abstract available


  116. WANDERS JOP, van Gils CH, Karssemeijer N, Holland K, et al
    The combined effect of mammographic texture and density on breast cancer risk: a cohort study.
    Breast Cancer Res. 2018;20:36.
    PubMed     Text format     Abstract available


  117. PADUA MB, Bhat-Nakshatri P, Anjanappa M, Prasad MS, et al
    Dependence receptor UNC5A restricts luminal to basal breast cancer plasticity and metastasis.
    Breast Cancer Res. 2018;20:35.
    PubMed     Text format     Abstract available


    April 2018
  118. HOUGHTON LC, Knight JA, De Souza MJ, Goldberg M, et al
    Comparison of methods to assess onset of breast development in the LEGACY Girls Study: methodological considerations for studies of breast cancer.
    Breast Cancer Res. 2018;20:33.
    PubMed     Text format     Abstract available


  119. GOORTS B, Dreuning KMA, Houwers JB, Kooreman LFS, et al
    MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer.
    Breast Cancer Res. 2018;20:34.
    PubMed     Text format     Abstract available


  120. CAMPA D, Barrdahl M, Santoro A, Severi G, et al
    Mitochondrial DNA copy number variation, leukocyte telomere length, and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study.
    Breast Cancer Res. 2018;20:29.
    PubMed     Text format     Abstract available


  121. LIU WS, Chan SH, Chang HT, Li GC, et al
    Isocitrate dehydrogenase 1-snail axis dysfunction significantly correlates with breast cancer prognosis and regulates cell invasion ability.
    Breast Cancer Res. 2018;20:25.
    PubMed     Text format     Abstract available


  122. WEISS A, Bashour SI, Hess K, Thompson AM, et al
    Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy.
    Breast Cancer Res. 2018;20:27.
    PubMed     Text format     Abstract available


  123. CHEN J, Wu X, Christos PJ, Formenti S, et al
    Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores.
    Breast Cancer Res. 2018;20:26.
    PubMed     Text format     Abstract available


  124. CABRERA RM, Mao SPH, Surve CR, Condeelis JS, et al
    A novel neuregulin - jagged1 paracrine loop in breast cancer transendothelial migration.
    Breast Cancer Res. 2018;20:24.
    PubMed     Text format     Abstract available


    March 2018
  125. TANG YC, Ho SC, Tan E, Ng AWT, et al
    Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer.
    Breast Cancer Res. 2018;20:22.
    PubMed     Text format     Abstract available


  126. EL ANSARI R, Craze ML, Miligy I, Diez-Rodriguez M, et al
    The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours.
    Breast Cancer Res. 2018;20:21.
    PubMed     Text format     Abstract available


  127. FROELUNDE AS, Ohlenbusch M, Hansen KB, Jessen N, et al
    Murine breast cancer feed arteries are thin-walled with reduced alpha1A-adrenoceptor expression and attenuated sympathetic vasocontraction.
    Breast Cancer Res. 2018;20:20.
    PubMed     Text format     Abstract available


  128. KNIGHT JA, Blackmore KM, Fan J, Malone KE, et al
    The association of mammographic density with risk of contralateral breast cancer and change in density with treatment in the WECARE study.
    Breast Cancer Res. 2018;20:23.
    PubMed     Text format     Abstract available


  129. ZEIDAN B, Manousopoulou A, Garay-Baquero DJ, White CH, et al
    Increased circulating resistin levels in early-onset breast cancer patients of normal body mass index correlate with lymph node negative involvement and longer disease free survival: a multi-center POSH cohort serum proteomics study.
    Breast Cancer Res. 2018;20:19.
    PubMed     Text format     Abstract available


  130. WANG X, Huang Y, Li L, Dai H, et al
    Assessment of performance of the Gail model for predicting breast cancer risk: a systematic review and meta-analysis with trial sequential analysis.
    Breast Cancer Res. 2018;20:18.
    PubMed     Text format     Abstract available


  131. BOYD N, Berman H, Zhu J, Martin LJ, et al
    The origins of breast cancer associated with mammographic density: a testable biological hypothesis.
    Breast Cancer Res. 2018;20:17.
    PubMed     Text format     Abstract available


  132. KIM H, Lin Q, Glazer PM, Yun Z, et al
    The hypoxic tumor microenvironment in vivo selects the cancer stem cell fate of breast cancer cells.
    Breast Cancer Res. 2018;20:16.
    PubMed     Text format     Abstract available


    February 2018
  133. SCHMIDT M, Weyer-Elberich V, Hengstler JG, Heimes AS, et al
    Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population.
    Breast Cancer Res. 2018;20:15.
    PubMed     Text format     Abstract available


  134. ALLOTT EH, Geradts J, Cohen SM, Khoury T, et al
    Frequency of breast cancer subtypes among African American women in the AMBER consortium.
    Breast Cancer Res. 2018;20:12.
    PubMed     Text format     Abstract available


  135. ROXANIS I, Colling R, Kartsonaki C, Green AR, et al
    The significance of tumour microarchitectural features in breast cancer prognosis: a digital image analysis.
    Breast Cancer Res. 2018;20:11.
    PubMed     Text format     Abstract available


    January 2018
  136. ANNIS MG, Ouellet V, Rennhack JP, L'Esperance S, et al
    Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion.
    Breast Cancer Res. 2018;20:9.
    PubMed     Text format     Abstract available


  137. WEBER-LASSALLE N, Hauke J, Ramser J, Richters L, et al
    BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer.
    Breast Cancer Res. 2018;20:7.
    PubMed     Text format     Abstract available


  138. YANG H, He W, Eriksson M, Li J, et al
    Inherited factors contribute to an inverse association between preeclampsia and breast cancer.
    Breast Cancer Res. 2018;20:6.
    PubMed     Text format     Abstract available


  139. MA H, Ursin G, Xu X, Lee E, et al
    Body mass index at age 18 years and recent body mass index in relation to risk of breast cancer overall and ER/PR/HER2-defined subtypes in white women and African-American women: a pooled analysis.
    Breast Cancer Res. 2018;20:5.
    PubMed     Text format     Abstract available


  140. BUSBY J, Mills K, Zhang SD, Liberante FG, et al
    Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study.
    Breast Cancer Res. 2018;20:4.
    PubMed     Text format     Abstract available


  141. LI N, Rowley SM, Thompson ER, McInerny S, et al
    Evaluating the breast cancer predisposition role of rare variants in genes associated with low-penetrance breast cancer risk SNPs.
    Breast Cancer Res. 2018;20:3.
    PubMed     Text format     Abstract available


  142. HUSS L, Butt ST, Almgren P, Borgquist S, et al
    SNPs related to vitamin D and breast cancer risk: a case-control study.
    Breast Cancer Res. 2018;20:1.
    PubMed     Text format     Abstract available


  143. PILLAI SG, Li S, Siddappa CM, Ellis MJ, et al
    Identifying biomarkers of breast cancer micrometastatic disease in bone marrow using a patient-derived xenograft mouse model.
    Breast Cancer Res. 2018;20:2.
    PubMed     Text format     Abstract available


    December 2017
  144. THOMSEN AML, Pedersen AB, Kristensen NR, Moller BK, et al
    Use of prescription drugs and risk of postoperative red blood cell transfusion in breast cancer patients: a Danish population-based cohort study.
    Breast Cancer Res. 2017;19:135.
    PubMed     Text format     Abstract available


  145. LI HY, Liang JL, Kuo YL, Lee HH, et al
    miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
    Breast Cancer Res. 2017;19:133.
    PubMed     Text format     Abstract available


  146. PARADA H JR, Sun X, Fleming JM, Williams-DeVane CR, et al
    Race-associated biological differences among luminal A and basal-like breast cancers in the Carolina Breast Cancer Study.
    Breast Cancer Res. 2017;19:131.
    PubMed     Text format     Abstract available


  147. YU J, Qin B, Moyer AM, Sinnwell JP, et al
    Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study.
    Breast Cancer Res. 2017;19:130.
    PubMed     Text format     Abstract available


    November 2017
  148. HELLAND T, Henne N, Bifulco E, Naume B, et al
    Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.
    Breast Cancer Res. 2017;19:125.
    PubMed     Text format     Abstract available


  149. JONES ME, Schoemaker MJ, Wright LB, Ashworth A, et al
    Smoking and risk of breast cancer in the Generations Study cohort.
    Breast Cancer Res. 2017;19:118.
    PubMed     Text format     Abstract available


  150. BAGEGNI N, Thomas S, Liu N, Luo J, et al
    Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
    Breast Cancer Res. 2017;19:123.
    PubMed     Text format     Abstract available


  151. HROMAS R, Kim HS, Sidhu G, Williamson E, et al
    The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells.
    Breast Cancer Res. 2017;19:122.
    PubMed     Text format     Abstract available


  152. AMANATULLAH DF, Tamaresis JS, Chu P, Bachmann MH, et al
    Local estrogen axis in the human bone microenvironment regulates estrogen receptor-positive breast cancer cells.
    Breast Cancer Res. 2017;19:121.
    PubMed     Text format     Abstract available


  153. OHNSTAD HO, Borgen E, Falk RS, Lien TG, et al
    Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
    Breast Cancer Res. 2017;19:120.
    PubMed     Text format     Abstract available


  154. BROUCKAERT O, Rudolph A, Laenen A, Keeman R, et al
    Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study.
    Breast Cancer Res. 2017;19:119.
    PubMed     Text format     Abstract available


    October 2017
  155. BERNHARDT S, Bayerlova M, Vetter M, Wachter A, et al
    Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors.
    Breast Cancer Res. 2017;19:112.
    PubMed     Text format     Abstract available


  156. TU CF, Wu MY, Lin YC, Kannagi R, et al
    FUT8 promotes breast cancer cell invasiveness by remodeling TGF-beta receptor core fucosylation.
    Breast Cancer Res. 2017;19:111.
    PubMed     Text format     Abstract available


    September 2017
  157. PELEKANOU V, Carvajal-Hausdorf DE, Altan M, Wasserman B, et al
    Erratum to: Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.
    Breast Cancer Res. 2017;19:109.
    PubMed     Text format    


    May 2017
  158. BRAMAN NM, Etesami M, Prasanna P, Dubchuk C, et al
    Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI.
    Breast Cancer Res. 2017;19:57.
    PubMed     Text format     Abstract available


  159. SAMENI M, Cavallo-Medved D, Franco OE, Chalasani A, et al
    Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ.
    Breast Cancer Res. 2017;19:56.
    PubMed     Text format     Abstract available


    March 2017
  160. ELSHOF LE, Schaapveld M, Rutgers EJ, Schmidt MK, et al
    The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study.
    Breast Cancer Res. 2017;19:26.
    PubMed     Text format     Abstract available


  161. UBELLACKER JM, Haider MT, DeCristo MJ, Allocca G, et al
    Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells.
    Breast Cancer Res. 2017;19:23.
    PubMed     Text format     Abstract available


    February 2017
  162. SCHOEMAKER MJ, Jones ME, Allen S, Hoare J, et al
    Childhood body size and pubertal timing in relation to adult mammographic density phenotype.
    Breast Cancer Res. 2017;19:13.
    PubMed     Text format     Abstract available


  163. TER BRAAK B, Siezen CL, Lee JS, Rao P, et al
    Insulin-like growth factor 1 receptor activation promotes mammary gland tumor development by increasing glycolysis and promoting biomass production.
    Breast Cancer Res. 2017;19:14.
    PubMed     Text format     Abstract available


    January 2017
  164. BARCUS CE, O'Leary KA, Brockman JL, Rugowski DE, et al
    Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells.
    Breast Cancer Res. 2017;19:9.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: